|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6399 USD | +1.06% |
|
+2.73% | +10.31% |
| Feb. 27 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Dec. 18 | RTW Biotech Opportunities announces new investment in Yarrow Bioscience | RE |
Company Valuation: VYNE Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54.59 | 8.705 | 32.52 | 49.42 | 19.31 | 21.32 | - | - |
| Change | - | -84.05% | 273.57% | 51.96% | -60.93% | 10.43% | - | - |
| Enterprise Value (EV) | 54.59 | 8.705 | 32.52 | 49.42 | 19.31 | 21.32 | 21.32 | 21.32 |
| Change | - | -84.05% | 273.57% | 51.96% | -60.93% | 10.43% | 0% | 0% |
| P/E ratio | -0.72x | -0.37x | -0.84x | -3.6x | -0.94x | -0.97x | -1x | -1x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.1x | 0x | -0.15x | 0.33x | - |
| Capitalization / Revenue | 3.7x | 18.3x | 76.7x | 98.6x | 33.9x | 91.4x | - | 3.14x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 91.4x | - | 3.14x |
| EV / EBITDA | - | - | -0x | -0x | -0x | -0.42x | -0.37x | -0.35x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.48x | -0.32x | -0.24x |
| EV / FCF | -0x | - | - | - | -0x | -0.38x | -0.26x | -0.18x |
| FCF Yield | -103% | - | - | - | -172% | -261% | -379% | -568% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -25.56 | -7.28 | -2.78 | -0.93 | -0.62 | -0.66 | -0.64 | -0.64 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 14.76 | 0.477 | 0.424 | 0.501 | 0.57 | 0.2333 | - | 6.8 |
| EBITDA 1 | - | - | -29.26 | -43.63 | -29.73 | -50.7 | -57.7 | -61.3 |
| EBIT 1 | -68.03 | -34.3 | -29.26 | -43.64 | -29.75 | -44.7 | -66.35 | -88.15 |
| Net income 1 | -73.33 | -23.21 | -28.45 | -39.83 | -26.48 | -44.13 | -66.25 | -88.05 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 18.3600 | 2.7000 | 2.3300 | 3.3500 | 0.5801 | 0.6399 | 0.6399 | 0.6399 |
| Nbr of stocks (in thousands) | 2,973 | 3,224 | 13,957 | 14,751 | 33,286 | 33,323 | - | - |
| Announcement Date | 3/17/22 | 3/9/23 | 2/29/24 | 3/6/25 | 2/27/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.97x | - | - | - | 21.32M | |
| 28.36x | 7.48x | 22.28x | 0.05% | 50.17B | |
| 16.9x | 5.07x | 11.51x | 1.75% | 43.62B | |
| -54.72x | 17.39x | -58.82x | -.--% | 30.43B | |
| -20.9x | 5.55x | -10.88x | -.--% | 28.22B | |
| -21.2x | 2544.1x | -29.53x | -.--% | 20.45B | |
| 28.04x | 5.48x | 15.23x | -.--% | 18.65B | |
| -444.22x | 34.97x | 4390.34x | -.--% | 17.26B | |
| 22.63x | 3.91x | 11.97x | -.--% | 16.71B | |
| -503.17x | 36.35x | -2284.69x | -.--% | 14.9B | |
| Average | -94.93x | 295.59x | 229.71x | 0.2% | 24.05B | |
| Weighted average by Cap. | -61.52x | 227.23x | 171.01x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VYNE Stock
- Valuation VYNE Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
